Global Immunosuppressive Drugs Market Research Report: By Drug Type
(Calcineurin Inhibitors, Corticosteroids, Antiproliferative Agents, mTOR Inhibitors,
Others), By Route of Administration (Intravenous, Oral, Others), By Application
(Autoimmune Disease, Organ Transplant, Kidney Transplant, Heart Transplant,
Others) and By End User (Hospitals and Clinics, Organ Transplant Centers, Others)
– Forecast to 2025
According to MRFR analysis, the global immunosuppressive drugs market is expected to
register a CAGR of ~4.63% during the forecast period of 2019 to 2025 and was valued at
USD 10,282 million in 2018.
Immunosuppressive drugs are antirejection medicines that obstruct or prevent activity of
the immune system. The growth of the global immunosuppressive drugs market is driven by
various factors such as the rising incidence rate of autoimmune diseases and increasing
cases of organ failures with the need for organ transplantation. However, the high costs of
transplantation procedures and the side effects of the drugs are expected to curb the
growth of the global immunosuppressive drugs market.
Get Sample Report at
The global Immunosuppressive Drugs Market is currently dominated by numerous market
players. The key players are involved in product launches and strategic collaborations to
strengthen their market positions. For instance, in May 2015, Pfizer, Inc. was granted US
Food and Drug Administration (FDA) approval for Rapamune (Sirolimus) for the treatment
of lymphangioleiomyomatosis (LAM).
Some of the key players in the global immunosuppressive drugs market are Accord
Healthcare (US), Astellas Pharma (Japan), F. Hoffmann-La Roche AG (Switzerland),
Genzyme Co. (US), GlaxoSmithKline PLC (UK), Bristol-Myers Squibb Company (US),
Glenmark Pharmaceuticals, Inc (India), Mylan Laboratories Inc. (US), Novartis AG
(Switzerland), Pfizer Inc. (US), Actavis, Inc. (US), and Zydus Cadila (India).